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Abstract
Background: Molecular characterization has the potential to advance the management of pediatric cancer and
high-risk hematologic disease. The clinical integration of genome sequencing into standard clinical practice has been
limited and the potential utility of genome sequencing to identify clinically impactful information beyond targetable
alterations has been underestimated.
Methods: The Precision in Pediatric Sequencing (PIPseq) Program at Columbia University Medical Center instituted
prospective clinical next generation sequencing (NGS) for pediatric cancer and hematologic disorders at risk for treatment
failure. We performed cancer whole exome sequencing (WES) of patient-matched tumor-normal samples and RNA
sequencing (RNA-seq) of tumor to identify sequence variants, fusion transcripts, relative gene expression, and copy
number variation (CNV). A directed cancer gene panel assay was used when sample adequacy was a concern.
Constitutional WES of patients and parents was performed when a constitutionally encoded disease was suspected.
Results were initially reviewed by a molecular pathologist and subsequently by a multi-disciplinary molecular tumor board.
Clinical reports were issued to the ordering physician and posted to the patient’s electronic medical record.
Results: NGS was performed on tumor and/or normal tissue from 101 high-risk pediatric patients. Potentially
actionable alterations were identified in 38% of patients, of which only 16% subsequently received matched
therapy. In an additional 38% of patients, the genomic data provided clinically relevant information of
diagnostic, prognostic, or pharmacogenomic significance. RNA-seq was clinically impactful in 37/65 patients
(57%) providing diagnostic and/or prognostic information for 17 patients (26%) and identified therapeutic
targets in 15 patients (23%). Known or likely pathogenic germline alterations were discovered in 18/90
patients (20%) with 14% having germline alternations in cancer predisposition genes. American College of
Medical Genetics (ACMG) secondary findings were identified in six patients.
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Conclusions: Our results demonstrate the feasibility of incorporating clinical NGS into pediatric hematology-oncology
practice. Beyond the identification of actionable alterations, the ability to avoid ineffective/inappropriate therapies,
make a definitive diagnosis, and identify pharmacogenomic modifiers is clinically impactful. Taking a more inclusive
view of potential clinical utility, 66% of cases tested through our program had clinically impactful findings and samples
interrogated with both WES and RNA-seq resulted in data that impacted clinical decisions in 75% of cases.
Keywords: Whole exome sequencing, RNA sequencing, Precision medicine, Pediatric oncology
Background
The outcomes for children with cancer have steadily im-
proved to the present time when more than 80% of all
pediatric oncology patients are cured [1]. Nonetheless,
cancer remains the leading cause of disease-related death in
children. Moreover, this success has come at a price; two-
thirds of all survivors have some long-term sequelae attribut-
able to their treatment [2]. Together, the requirement to
further improve existing outcomes and to decrease toxicity
underscores the need for the current national initiative in
precision medicine to include pediatric oncology patients.
Many of the advances in pediatric oncology have resulted
from the implementation of risk-stratified treatment strat-
egies that incorporate histological, anatomical, and molecu-
lar prognostic and predictive determinants into the choice
of therapies for individual patients [3]. Changes in ploidy,
chromosomal segmental changes, and specific gene alter-
ations are routinely utilized to guide treatment intensity in
pediatric oncology [4]. Therefore, the tenants of precision
medicine are intrinsic to the practice of pediatric oncology.
Recent advances in massively parallel sequencing allow
for more comprehensive approaches to determine the
abnormalities contributing to tumorigenesis. Initial
implementation of next generation sequencing (NGS)
technologies focused on the identification of actionable
alterations, with estimates in the range of 5% to nearly
100% depending on disease histology and evolving defini-
tions of “actionable” [5–15]. The utility of these technolo-
gies, however, extends well beyond the identification of
actionable alterations and determining the value of these
technologies should be more inclusive and consider the
broad clinical impact of testing.
In 2014, we implemented a clinical NGS platform for
pediatric oncology patients. The Precision in Pediatric
Sequencing (PIPseq) Program utilizes NGS of tumor
and germline in a CLIA-certified (Clinical Laboratory
Improvement Amendments of 1988) environment and
includes interrogation of both DNA and RNA. We con-
ducted a retrospective review of our first 101 consecu-
tively sequenced patients utilizing the PIPseq pipeline
and report here our experience with integrating clinical
NGS into pediatric hematology-oncology practice and




To achieve more comprehensive genome-level analysis
in our pediatric oncology patients, we utilized three
CLIA-certified, CAP (College of American Pathologists),
and New York State Department of Health approved
assays. When possible, we utilized a cancer whole exome
sequencing test (cWES) comprising WES of tumor and
normal tissue (buccal swab or peripheral blood) and
RNA sequencing (RNA-seq) of tumor tissue. This assay
was optimized for fresh or frozen specimens. When
sample adequacy was a concern, we also utilized a di-
rected cancer gene panel assay which sequenced 467
cancer-associated genes and was optimized for use with
formalin fixed paraffin embedded (FFPE) material
(Columbia Comprehensive Cancer Panel, CCCP). If a
constitutionally encoded disease was suspected (e.g.
familial hemophagocytic lymphohistiocytosis), we per-
formed constitutional WES from the patient and both
parents (trio) when available.
Tissue for sequencing was obtained either from ar-
chived blocks (FFPE) or frozen tissue blocks from the
Department of Pathology. DNA and RNA extraction and
sequencing were performed in a CLIA-certified labora-
tory. Variant calls were independently made on tumor
and germline material and somatic variants determined
by subtraction. Copy number variation (CNV) was de-
termined from the WES data, fusion transcripts were
identified from the RNA-seq data, and relative gene ex-
pression was determined by comparison to a model built
from 124 transcriptomes. A mix of tissues was used to
generate the model including normal white blood cells,
lung, liver, brain, glioma, and cell lines.
After initial review by a molecular pathologist, all re-
sults were reviewed in a multi-disciplinary molecular
tumor board. Participants included representation by
molecular pathology, pediatric oncology, cytogenetics,
medical genetics, and cancer biology. For each patient, a
report was issued containing variant calls, CNV, fusions,
and overexpressed genes. Variants were assigned a tier
based on disease-association and separately a tier based
on level of evidence for clinical actionability (described
below). Reports were delivered to ordering oncologists
and posted to the electronic medical record (EMR) in
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accordance with patient opt-in/opt-out preferences se-
lected at the time of informed consent.
Patients and informed consent for clinical sequencing
Between January 2014 and April 2016, NGS was per-
formed on tumor and/or normal tissue from 101 high-risk
patients by the Laboratory of Personalized Genomic
Medicine at Columbia University Medical Center
(CUMC). This represented approximately 32% of the total
patients in our clinical practice. High-risk patients were
defined as those having a prognosis of <50% overall
survival at 5 years, outlier clinical phenotype, rare cancer
without standard of care therapy, suspected cancer
predisposition, or relapsed disease. A request for constitu-
tional WES, cWES and RNA-seq, or targeted cancer panel
testing was made at the discretion of the referring oncolo-
gist in consultation with the PIPseq team [16].
Participants signed consent for WES or cWES either
as part of an Institutional Review Board (IRB)-approved
protocol (IRB nos. AAAB7109, AAAJ5811) or they
signed the clinical consent (http://pathology.columbia.
edu/diagnostic/PGM/oncologytests.html). Written con-
sent for clinical WES and cWES testing was obtained
after the risks and benefits had been explained to the
patient and/or caregiver, which include the potential
disclosure of medically actionable secondary findings,
defined as germline disease-causing mutations unrelated
to the condition for which sequencing was being per-
formed. Patients could opt in or opt out of the following:
learning secondary findings and/or having these results
appear in the EMR; having their samples and/or data
stored for future research, both with or without identi-
fiers; and future contact. Results not reported included
carrier status, variants of uncertain significance (VOUS)
in secondary findings except as related to cancer, and
mutations related to adult-onset conditions for which
the genetic link is either unclear or for which no known
intervention is of proven benefit (e.g. Alzheimer’s dis-
ease). IRB approval was obtained for this retrospective
analysis of de-identified patient and clinical genomics
data (IRB nos. AAAP1200 and AAAQ8170).
Clinical sequencing
Testing required at least 200 ng of DNA for WES, at least
50 ng of DNA for targeted DNA sequencing, and at least
3000 ng of RNA for transcriptome analysis (Additional file
1: DNA and RNA extraction). The entire assay was a
CLIA-certified assay. The laboratory-developed test used
general purpose reagents and the Agilent WES ver.5 +
UTR baits. Specifically, WES was performed using the
Agilent SureSelectXT All Exon V5 +UTRs capture kit
for library generation and sequenced on the HiSeq2500
using paired-end 125 cycle × 2 sequencing (two
tumors, two normal and two transcriptomes, pooled
together and run in two lanes). Targeted DNA sequen-
cing was performed on a 5.59 Mb Custom Agilent
SureSelectXT library, targeting 467 genes, and sequenced
on a HiSeq2500 using paired-end 125 cycle × 2 sequencing
(seven samples per lane). RNA was sequenced using the
TruSeq Stranded Total RNA LT Sample Prep Kit with 125
cycles × 2 paired-end sequencing on the HiSeq2500.
Sequencing analysis
DNA sequencing reads were de-multiplexed and con-
verted to fastq files using CASAVA from Illumina.
Mapping and variant calling of tumor and normal sam-
ples was performed using NextGene (v.2.3.4; Softge-
netics, State College, PA, USA), which uses a modified
Burrows-Wheeler transform (BWT) alignment method.
Sequences were mapped to GRCh37 (“hg19”), retaining
reads with a median quality score of 20 or higher, with
no more than three ambiguous bases, a minimum num-
ber of 25 called bases per read, and trimming reads
when three consecutive reads fell below a quality score
of 16. Alignment and variant calling was performed
using paired-end reads with a minimum of 10 reads, at
least three variant reads, and a minimum variant allelic
fraction of 10% for tumor and 5% for normal was re-
quired to call a variant. The variant calling module was
set to “detect large indels.” The variant calling algo-
rithm showed a 99.6% agreement with single nucleotide
polymorphisms on an oligonucleotide microarray and
over 96% sensitivity in inter-laboratory comparison and
a 96% detection rate for heterozygous variants in a 40/
60% mixture of samples. For small indels, the lab de-
tected 93% of all variants detected by another labora-
tory in inter-laboratory comparison, with the greatest
disagreement in insertions greater than 10 bp.
Variants were subject to filtering. In normal DNA,
variants were passed through a “reference range filter” of
cancer predisposition genes, genes relevant to pharma-
cogenomics, and variants relevant to patient care; a
“reportable range filter” which includes COSMIC
(cosmic70 provided by Annovar) variants in the patient’s
mutation report file and variants in genes recommended
by the American College of Medical Genetics (ACMG)
for the reporting of secondary findings [17]; as well as a
frequency filter, which includes variants whose minor
allele frequency in the 1000 Genomes (phase 1, version 3,
release date 23 November 2010) is less than 1%. Somatic
mutations in the tumor were identified by subtracting all
variants called in normal tissue (output at minor allelic
fraction of ≥5%) from variants called in the tumor (output
at a minor allelic fraction of ≥10%). The approach maxi-
mized the number of variants output to minimize the
likelihood of filtering out actionable mutations prior to
molecular tumor board discussion (Additional file 1:
Supplementary Methods; Somatic Variant Calling Strategy).
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Variants in the tumor were further characterized as
homozygous, compound heterozygous, somatic, and
“disruptive” (loss of function, namely, nonsense, frame-
shift, or splice site). Spreadsheets with the various cat-
egories were presented to molecular pathologists for re-
view. Quality statistics for WES and cWES are presented
in Additional file 2: Table S1. Targeted DNA sequencing
was performed to an average 500X depth and analyzed
as above. All DNA sequencing results were manually
reviewed by molecular pathologists to prioritize variants
for presentation at the multi-disciplinary tumor board
and subsequent reporting of consensus variants. For
mutation statistics, the list of “tumor-specific” variants
obtained by comparison of vcfs was filtered for variants
with at least 30X coverage in tumor and either a “quality
score” ≥20 or a variant allelic fraction ≥25% in the tumor.
Copy number variation
CNV was identified using EXCAVATOR (v.2.2; https://
sourceforge.net/projects/excavatortool) software [18].
For samples with greater than 95% of targeted nucleo-
tides present at least 10X in the reference normal and
at least 90% covered 30X in the corresponding tumor
sample, EXCAVATOR was run with parameters chosen
for moderate sensitivity (assuming a tumor percentage
of 0.8) and cutoff for loss set to a log2 ratio of –0.2. In
addition, all high quality heterozygous variants with vari-
ant allelic fractions (VAFs) in the range of 45–55% and
90–100% in the normal sample were output. The allelic
ratio at these genomic coordinates in the tumor was also
output for viewing on the integrated genomic viewer to
allow identification of copy number neutral loss of
heterozygosity (LOH) and to support the CNVs identified
by EXCAVATOR. The laboratory detected all chromo-
some arm changes seen on karyotyping, losses of 26 Mb
and greater seen on array CGH, and reproducibly identified
all CNVs that involved at least ten exons at 40% tumor
fraction (Additional file 1: Supplementary Methods).
Transcriptome analysis
For transcriptome analysis, fastq files from CASAVA
were filtered for ribosomal RNA (rRNA) using Sort-
MeRNA (v.1.7; http://bioinfo.lifl.fr/RNA/sortmerna/)
and trimmed to remove poor-quality tails using Trim-
Galore (v.0.2.7; http://www.bioinformatics.babraham.ac.
uk/projects/trim_galore/) with settings to exclude reads
of quality score <20 and read length <20. Remaining
reads were mapped to GRCh37 (hg19) using Tuxedo
Suite [19, 20] consisting of TopHat2 (v.2.0.8), BOW-
TIE2 (v.2.1.0), and CUFFLINKS (v.2.1.1). Non-uniquely
mapped reads were excluded before estimation of
fragments per kilobase per million reads (FPKMs) by
CUFFLINKS. Mutation calling was performed using
NextGene software. At least 50 million uniquely
mapped reads were required with less than 5% DNA
contamination. In addition, unmapped reads were ana-
lyzed using “FusionMap” (v.01/01/2015) to generate a
list of fusions for review by molecular pathologists [21].
To identify alterations in gene expression, the median
FPKMs of 8000 housekeeping genes were used as refer-
ence [22] and the relative expression of each gene was
compared to 124 normal transcriptomes from various
tissues (13 blood, 20 liver, 24 kidney, 17 lung, and 50
brain) (Additional file 1: Supplementary Methods).
Data interpretation and reporting
Interpretation of clinical WES, RNA-seq, and CNV was
conducted via a molecular tumor board with multi-
disciplinary representation from pediatric oncology, path-
ology, cancer biology, molecular and clinical genetics, and
bioinformatics. Following the tumor board, approximately
60 days after testing request, a tiered report was generated
for clinical samples by pathology, sent to the referring
physician and posted to the EMR according to the opt-in/
opt-out selections of the patient consent. Only variants
with good normal coverage (generally at least 30X) were
detected on multiple independent fragments and were not
excluded as likely benign were reported. For clinical test-
ing, the report included variants that were justified by the
literature as driver mutations (e.g. well characterized hot
spot mutations); unambiguous loss of function mutations
in tumor suppressor genes (i.e. nonsense or frame-shift
mutations that resulted in loss of functional domains); mu-
tations with published laboratory data documenting gain
or loss of function in oncogenes and tumor suppressor
genes, respectively; and previously reported fusions or fu-
sions that were expected to have the same effect as previ-
ously reported fusions involving one of the partner genes.
Certain exceptions for clinical testing were made. For ex-
ample, if a variant was likely a strong driver (e.g. a known ac-
tivating mutation of an oncogene) but had low coverage in
the normal or appeared low-quality on review, the molecular
pathologist still considered it but required independent
confirmation by an orthogonal method prior to reporting.
The final clinical cWES report included: known
tumor type-specific actionable somatic mutations (Tier
1); somatic mutations in targetable pathways, actionable
somatic mutations in other tumor types, somatic muta-
tions in well-established cancer genes (Tier 2); other
somatic mutations in cancer genes (Tier 3); and som-
atic VOUS (Tier 4). Reporting of germline findings
included: known pathogenic secondary ACMG variants
[17]; secondary non-ACMG variants and selected
VOUS in known cancer genes with commentary; and
known variants that influence pharmacogenomics.
Reports further included translocations, significantly
overexpressed genes, and segmental CNV. A sample
cWES report is presented in Additional file 3. Accession
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number for all genes and fusions referenced in the paper
are reported in Additional file 2: Table S2. Datasets are
available through the cBioPortal for Cancer Genomics
(http://cbioportal.org) [23, 24].
Clinical utility, defined as the ability of a molecular
test result to provide information related to the care of
the patient and his/her family members to diagnose,
monitor, prognosticate or predict disease progression,
and inform treatment [25], was used to evaluate the
potential impact of findings from clinical sequencing.
“Clinical impact” and “clinically impactful” are broad
terms used throughout this paper to refer to any mo-
lecular test result that, when integrated with a patient’s
history, symptoms, and other clinical findings, informed
the medical team’s assessment or management of the
patient. These clinically meaningful results were subca-
tegorized into the following five categories to evaluate
the potential clinical utility of tumor and germline alter-
ations: (1) diagnostic; (2) prognostic; (3) identification of
a therapeutic target; (4) other clinically impactful infor-
mation, including pharmacogenomics or findings that
resulted in a significant refinement of a therapeutic plan
(e.g. choice of donor or withdrawal of recommendation
for bone marrow transplantation); and (5) recommenda-
tions for health maintenance interventions or genetic
counseling for the patient and other at-risk family
members. Genetic alterations were considered targetable
if: (1) an FDA approved drug or experimental drug was
available that inhibited the target directly or inhibited
its downstream signaling pathway; or (2) there was pre-
clinical evidence to support efficient targeting of the
aberrant function of the mutated gene and/or potential
clinical benefit; and (3) there was some age-appropriate
information on dosing. Targetable somatic mutations
were further categorized using a five-tier system previ-
ously described by Wagle et al. [26] and Harris et al.
[15]. This sub-tiering system uses the strength of
preclinical and clinical data as evidence to support the
potential clinical benefit of targeting an altered gene
with a specific therapeutic agent.
Results
Patients
Demographic and clinical characteristics are presented
in Table 1 and Fig. 1. Molecular characterization was
performed on 120 samples (85, primary disease; 35,
relapse/refractory disease) from 101 consecutive cases
(mean age, 9.3 years; median age, 8.0 years; range, 2
weeks – 26 years). Patients aged over 18 years in this co-
hort were initially diagnosed with a pediatric disease
under the age of 18 years. Testing included: full cWES
(tumor, germline, and transcriptome; n = 63); cWES
without transcriptome (n = 19); transcriptome only (n =
3); targeted tumor panel sequencing (n = 13); and
constitutional WES (proband and parental blood) (n =
22). For constitutional WES, trios (proband and both
parents) were performed in 18/22 cases, 3/22 cases only
had one parent available for testing, and in one case
only the proband was tested post-mortem. Eighty-four
patients underwent single platform testing, while mul-
tiple sequencing platforms were used for 17 cases (36
samples). Cases were predominantly pediatric patients
with solid tumors (64%) (Fig. 1; Additional file 2: Table
S3). Sarcoma (n = 17) was the most common diagnostic
sub-category followed by brain tumors (n = 16). Patients
with lymphoid disease (n = 17) comprised the majority
of hematological conditions (Fig. 1; Additional file 2:
Table S3).
Informed consent, cost, and reimbursement
All patients were consented to genomic analysis either
through a research consent or clinical WES consent.
Of the 101 cases, 67 were consented using the clinical
cWES consent. Only four (6%) opted out of learning
secondary findings and 21 (31%) opted out of having
Table 1 Patient and sample characteristics (n = 101)
n (%)
Diagnostic category
Solid tumors 65 (64)









Samples tested (n = 120)
Primary disease 85 (71)
Relapse/refractory 35 (29)
Platform (n = 120)
Cancer WES with transcriptome 63 (53)
Cancer WES 19 (16)
Constitutional WES 22 (18)
Transcriptome only 3 (2)
Targeted panel (467 genes) 13 (11)
Normal tissue source (n = 104)
Blood 78 (74)
Buccal swab 23 (23)
Unaffected tissue 3 (3)
WES whole-exome sequencing
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secondary findings in their medical record. All patients
consented to have leftover samples stored. Only a
single patient (2%) opted out of future contact
(Additional file 2: Table S4).
As part of clinical implementation, we assessed the
cost of cWES and RNA-seq and the reimbursement
landscape. The total cost per case was calculated by
summing the total variable cost (reagent cost, patholo-
gist time) with the fixed cost per case (annual machine
cost, annual maintenance, tech labor cost, informatics
cost, space for NGS hardware, server time, NGS analysis
lease, and data storage). The estimated cost of WES
(tumor/normal) was $4459 and the cost of RNA-seq was
$1764. These estimates do not include administrative
overhead and billing for services.
The time to receiving final reimbursement decisions
from third-party payers ranged between 6 months to
1 year. To date, we have received a decision for 56
patients with 45/56 (80%) receiving partial reimburse-
ment. The average reimbursement by carrier type was
as follows: commercial, $2747 (range, $770–6917);
managed government plans, $2918 (range, $750–
4555); and $0 from government plans. Patients and
their families were not charged for sequencing or
analysis.
Genomic alterations in pediatric solid tumors and
hematologic disorders
Over 150-fold and 500-fold average coverage was
achieved by WES and targeted capture sequencing,
respectively with >98% of the coding sequences having
at least tenfold coverage. The mean mutational load
across patients was 216.9 variants (SD = 829.3, median
= 69), with a higher mean mutational load in solid
tumors compared to hematologic malignancies (Fig. 2;
Additional file 4: Figure S1). Genomic aberrations were
reported in 92/101 patients (91%). After filtering, a
total of 180 mutations (Additional file 2: Table S5) and
20 fusions were reported, 110 (including 10 fusions)
from solid tumor samples (mean number of aberrations
per sample, 2.91; median, 2.00; range, 1–6) and 90 (in-
cluding 10 fusions) from hematologic samples (mean
number of aberrations per sample, 5.2; median, 4.0;
range, 1–12). The most commonly mutated gene was
TP53 (n = 9, 9%) in solid tumor samples and RAS path-
way constituents (NRAS: n = 5, 5%; KRAS: n = 3, 3%) in
hematologic samples (Fig. 3). In addition, significant
changes in the pattern of genetic alterations were noted
on serial sequencing of samples from individual patients
at different time points during their therapy, reflecting
clonal evolution. Awareness of these changes is important
Fig. 1 PIPseq overview. An overview of the PIPseq patients sequenced is presented on the left and a pie chart showing the distribution of
diagnostic categories on the right
Oberg et al. Genome Medicine  (2016) 8:133 Page 6 of 19
for selecting an appropriate targeted therapy and assessing
response to therapy.
Evaluating potential clinical utility and targetable alterations
A genetic variant was considered targetable if: (1) an
FDA-approved drug or experimental drug was available
that inhibited the target directly or inhibited its down-
stream signaling pathway; or 2) there was preclinical
evidence to support efficient targeting of the aberrant
function of the mutated gene and/or potential clinical
benefit; and 3) there was some age-appropriate infor-
mation on dosing. Consistent with the published rec-
ommendations from the Association for Molecular
Pathology [25], we evaluated clinical utility based on
“the ability of a test result to provide information to the
patient, physician, and payer related to the care of the
patient and his/her family members to diagnose, moni-
tor, prognosticate, or predict disease progression, and
to inform treatment and reproductive decisions.”
Targetable somatic genomic alterations
Overall, 38/101 patients (38%) had at least one poten-
tially targetable genomic alteration (Table 2). Specifically,
21/65 patients (32%) with solid tumors and 17/36 (47%)
patients with hematologic conditions carried targetable
alterations. Matched therapy based on genomic findings
was received in 6/38 patients (16%).
Examples of targetable alterations include the iden-
tification of a cKIT (p.Asn655Lys) [27] mutation in a
7-year-old boy with acute myeloid leukemia (AML),
who was subsequently treated with palliative imatinib
and achieved a near-complete clearing of peripheral
blood leukemic blasts with a sustained response for 9
months. The RNA expression data also led us to iden-
tify a BCR-ABL1-like [28] expression pattern in a 9-
year-old girl with relapsed, refractory B-cell acute
lymphoblastic leukemia (ALL). Subsequent analysis
identified a NUP214-ABL1 [29] fusion by real-time
polymerase chain reaction (RT-PCR) and the addition
of dasatinib to the third-line induction regimen re-
sulted in a deep remission allowing for a curative bone
marrow transplant. These results demonstrate the util-
ity of comprehensive genomic characterization to iden-
tify clinically actionable alterations in pediatric
oncology patients.
Clinical impact of non-targetable somatic mutations
While many studies have focused on actionable alter-
ations, the potential clinical impact of non-targetable
alterations was also evaluated. Genomic alterations
identified by sequencing helped to confer a molecular
diagnosis in 23 patients and identified prognostic,
pharmacogenomic, and other significant health main-
tenance recommendations in 32 patients (Table 3).
Although these findings do not meet the definition of
“actionability,” the clinical impact of such findings can
be quite profound. For example, the identification of a
STAT5B mutation [30] in a 5-year-old girl erroneously
diagnosed with T-cell ALL helped to establish a diagno-
sis of gamma-delta T-cell lymphoma. Also, identifica-
tion of a PTPN11 mutation in a 4-year-old boy
contributed to a change in his diagnosis from de novo
AML to juvenile myelomonocytic leukemia (JMML)
which evolved into AML [31].
The identification of resistance alleles likewise is not
considered actionable, but may carry significant clinical
implications. For example, in the 9-year-old girl with the
relapsed NUP214-ABL1 B-ALL, the finding of a NT5C2
mutation associated with resistance to nucleoside analog
therapies [32, 33] had clear implications for her salvage
therapy. In aggregate, sequencing results were clinically
informative for diagnostic, prognostic, or pharmacoge-
nomic purposes in 38 patients (38%).
Clinical impact of transcriptome and CNV analysis beyond
target identification
Clinical impact by RNA-seq and CNV analysis was dem-
onstrated in 23/33 patients (70%) (Table 3). Gene fusions
confirming diagnosis were found in five patients: BCR-
ABL1 (chronic myeloid leukemia), ASPSCR1-TFE3 (al-
veolar soft part sarcoma), EWSR1-FLI1 in two patients
Fig. 2 Somatic mutation load by diagnostic category. Box plots
comparing overall somatic mutation rates across solid tumors and
hematologic conditions detected by NGS. The top and bottom
ends of the boxes represent the 25th and 75th percentile values,
respectively, and the segment in the middle is the median. The
top and bottom extremes of the bars extend to the minimum and
maximum values. The box plot depicts the total mutation load
excluding four outliers (one solid tumor and three hematologic).
See Additional file 4: Figure S1 for inclusive dataset with outliers.
The total mutational load (prior to filtering or orthogonal validation)
for solid tumors was 4972 variants (mean, 84.3; SD, 43.9; median, 85;
range, 15–214) and for hematologic conditions was 1478 variants
(mean, 56.85; SD, 34.9; median, 47; range, 14–149)
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(Ewing sarcoma), and EWSR1-WTI (desmoplastic small
round cell tumor). A novel EML4-NTRK3 fusion found
in a 2-year-old boy supported a change in diagnosis
from undifferentiated sarcoma to infantile fibrosarcoma
[15, 34]. In one patient, a CBFA2T3-GLIS2 [35] fusion
confirmed the diagnosis of acute megakaryoblastic
leukemia (AMKL), was associated with poor prognosis,
and supported the recommendation for a bone marrow
transplant. A PAX7-FOXO1 fusion was diagnostic and
prognostic in a toddler with histologically defined solid
alveolar rhabdomyosarcoma, but in whom FISH ana-
lysis using the FOXO1A (FKHR; 13q14.1) break-apart
probe was repeatedly negative.
CNV was inferred from the WES data and relative
gene expression was determined by reference to an aver-
aged gene expression model. Segmental and gene
expression changes having prognostic implications were
identified in 11 patients with a variety of diagnoses. Four
patients diagnosed with neuroblastoma could be strati-
fied based on RNA-seq and CNV: one high-risk patient
with MYCN amplification, LOH at 1p and 11q, gain of
17q, and MYCN overexpression; one high-risk patient
with MYCN amplification, LOH at 1p, gain of 17q, and
MYCN overexpression; one high-risk patient without
MYCN amplification or LOH at 1p and 11q, and no
evidence of MYCN overexpression; and one intermediate-
risk patient without MYCN amplification or LOH at 1p
and 11q and no evidence of MYCN overexpression.
Medulloblastoma subgrouping was supported by over-
expression and CNV in two patients. Poor prognostic
features were found in two other patients: low expression
of PAX8, FHIT, CASP10, CHD2, with high expression
Fig. 3 Summary of informative results from the PIPseq program. A matrix representation of findings with biological significance from the
sequencing results are presented. Data are derived from all 101 patients that underwent WES of tumor-normal sample pairs, exome sequencing
of germline DNA, transcriptome analysis of tumor, CNV of tumor, and targeted panel sequencing of tumor only. Deleterious mutations were
loss of function mutations and activating mutations refers to recurrent, previously reported activating mutations in oncogenes or variants with
published in vitro evidence as being activating
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Table 2 Sub-classification of potentially targetable somatic mutations for treatment planning
PIP ID Diagnosis Target alteration Mutation (change) Potential target therapy
Tier 1 (Data demonstrating benefit- same tumor type, same gene)
14-85546 CML BCR-ABL1 Fusion TKI
13-45348a AML IDH1 c.394C > T (p.R132C) IDH Inhibitor
14-24794a AML c-KIT; TET2; FLT3 c.2446G > C (p.D816H); c.3663delT
(p.C1221Wfs); c.2505 T > G (p.D835E)
TKI; Hypomethylating
agent; TKI
14-53198 AML TET2 c.1156G > T (p.V386L) Hypomethylating agent
13-77086 AML c-KIT c.1965 T > G (p.Asn655Lys) TKIb
Tier 2 (Data demonstrating benefit- different tumor type, same gene)
15-18928 Hepatic rhabdoid tumor SMARCA4 c.3574C > T (p.R1192C) EZH2 Inhibitor
14-13487 Osteosarcoma TSC1 c.2503-1G > C (p.?) mTOR Inhibitor
14-47205 Nephroblastomatosis PIK3CA c.1035 T > A (p.N345K) PI3K/AKT/mTOR Inhibitor
15-40141 Pleomorphic
xanthoastrocytoma
TMEM106B-BRAF Fusion MEK Inhibitor
Tier 3 (Published, presented, in press pre-clinical data demonstrating benefit- same tumor type, same gene)
15-64793 ALL FOXP1-ABL1 Fusion TKIb
15-26188 ALL NUP214-ABL1 Fusion TKIb
15-79700 ALL NRAS c.183A > T (p.Q61H) MEK Inhibitor
14-20062 ALL KRAS c.183A > T (p.Q61H) MEK Inhibitor
14-24794a AML NRAS c.183A > C (p.Q61H) MEK Inhibitor
15-29224 AML JAK3 c.1718C > T (p.A573V) JAK Inhibitor
13-45348a AML NRAS c.38G > C (p.G13A) MEK Inhibitor
13-95124 AML NRAS; MLL-AFF1 (KMT2A-AFF1) c.182A > G (p.Q61R); Fusion MEK Inhibitor;
DOT1L Inhibitor
14-45760 AML NRAS c.38G > A (p.G13D) MEK Inhibitor
13-50662 AML PTPN11 c.1508G > T (p.G503V) MEK Inhibitor
14-15491 AML NUP98-NSD1 Fusion DOT1L Inhibitor
14-27243 Neuroblastoma NRAS c.181C > A (p.Q61K) MEK Inhibitor
14-70449 Rhabdomyosarcoma NRAS c.181C > A (p.Q61K) MEK Inhibitor
14-42817 Neuroblastoma KRAS c.34G > T (p.G12C) MEK Inhibitor
15-11925a Osteosarcoma MYC Overexpression BET Inhibitor
16-74654 Rhabdomyosarcoma FGFR4 c.1582G > T (p.G528C);
c.1648G > C (p.V550L)
FGFR4 Inhibitor
15-23518 Rhabdomyosarcoma FGFR4 c.1648G > C (p.V550L); c.1949G > T
(p.R650L); Overexpression
FGFR4 Inhibitor
14-37237 Glioblastoma multiforme Gain 12q.14.1 involving CDK2 Copy number CDK4/6 Inhibitor
15-44470 Medulloblastoma PTCH1, SUFU, ZIC3 Overexpression SMO Inhibitor
15-10838 Glioma H3F3A; FGFR1 c.83A > T (p.K28M);
c.1731C > A (p.N577K)
HDAC Inhibitor
15-27992 Hepatic rhabdoid tumor Homozygous deletion of chr 22q11.23
with homozygous deletion of SMARCB1;
Loss of expression of SMARCB1
Copy number; Loss of expression
with biallelic deletion
EZH2 Inhibitor
Tier 4 (Published, presented, in press pre-clinical data demonstrating benefit- different tumor type, same gene)
15-36388 AML MLL3 (KMT2C) c.2110G > T (p.E704X) BET Inhibitor
13-72282 T-ALL KRAS; JAK1; STAT5B c.40G > A (p.V14I); c.3076A > G
(p.K1026E); c.2110A > C (p.I704L)




ALK c.3436C > A (p.Q1146K) ALK Inhibitorb
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of CHD11, FUS, and MTA1 in a patient with Ewing
sarcoma [36], and gain of 1q and loss of 6q and overex-
pression of TNC, CALB1, PLAG1, ALDH1L1, and
RELN in a patient with ependymoma [37]. Overexpres-
sion of CCND1 in a patient with hepatoblastoma was
considered a good prognostic indicator. One patient
with AML with a CBFB-MYH11 fusion could be
assigned to risk-based therapy and the diagnosis of
gamma-delta T-cell lymphoma [38, 39] was also corrob-
orated by CNV with isochromosome 7q.
Clinically impactful germline alterations
A total of 90 patients had germline tissue sequenced.
Cancer WES included germline analysis in 68/90 pa-
tients. Tumor sequencing plus constitutional WES was
performed in eight patients and 14 patients had only
germline tissue sequenced for a variety of indications
including clinical suspicion of cancer predisposition or
of an underlying immunologic defect responsible for the
development of lymphoma or hemophagocytic lympho-
histiocytosis (HLH).
Clinically impactful germline alterations (Table 4) were
found in 18/90 patients (20%): 11/57 patients with solid
tumors (19%) and 7/33 patients with hematologic condi-
tions (21%). In the solid tumor category, two alterations
in APC were diagnostic: one in a patient with hepato-
blastoma and a family history consistent with familial
adenomatous polyposis (FAP; p.R1114) and one associated
with newly appreciated Gardner’s syndrome (p.E1554fs) in
a 14-year-old boy with pilomatricomas and epidermoid
cysts prior to his carcinoma diagnosis. Two variants in
ATM (p.R189K, p.K2756*) were found in a 16-year-old
boy with medulloblastoma inferring an increased risk for
developing other cancers. All were referred for genetic
counseling and consideration for future cancer screening
in the patient and family.
In patients with hematologic conditions, the incidence of
germline alterations related to the primary diagnosis was ob-
served in five patients (15%). A homozygous pathogenic
variant in C1QA (p.Gln208Ter) diagnostic of C1Q defi-
ciency was identified in a 2-year-old girl with HLH. A
homozygous pathogenic variant in PMS2 (p.S459X) diag-
nostic of congenital mismatch repair deficiency was identi-
fied in one patient with T-cell lymphoblastic lymphoma and
consanguineous parentage [40]. A likely pathogenic variant
in XIAP (p.R443P) was identified in a 6-year-old girl with
HLH, recurrent EBV infections, and suspected underlying
immunodeficiency. Germline testing also revealed a hetero-
zygous pathogenic splicing variant in RUNX1 (c.806-2A >G,
r.Spl) in a patient with AML referred for transplantation for
persistent thrombocytopenia following chemotherapy [41].
Both an HLA-matched sibling with borderline low platelets
and the father were found to carry the same variant. An un-
related donor source was selected. A 2-month-old patient
hospitalized for fulminant hemophagocytic syndrome was re-
ferred for evaluation of presumed familial HLH and was con-
sidered for hematopoietic stem cell transplantation. However,
germline WES identified a pathogenic homozygous mutation
inMLL2 (p.M3881Cfs*9) establishing the diagnosis of Kabuki
syndrome [42] and familial HLH was ruled out due to the
lack of alterations in any HLH-associated genes and subse-
quently plans for a bone marrow transplant were averted.
ACMG secondary findings were identified in six patients
(Table 4) and were returned to the families by clinical gen-
etics. A germline BRCA1 mutation was discovered in an
18-year-old boy with a rare hepatic tumor and a 17-year-
old girl with ependymoma. A TP53 mutation was found in
a 1-year-old girl with AML, a TNNT2 mutation associated
with dilated cardiomyopathy was found in a 15-year-old
boy with osteosarcoma, a RYR1 mutation associated with
malignant hyperthermia was found in a 7-year-old girl with
neuroblastoma, and a mutation in VHL was found in a
2-year-old boy with ependymoma.
Table 2 Sub-classification of potentially targetable somatic mutations for treatment planning (Continued)
Tier 5 (Anything else the molecular tumor board thought was sufficient to qualify for treatment planning)
15-16072 ALL SMARCC2-PDGFRB Fusion TKI
14-75899 Neuroblastoma CDK4, MDM2 Overexpression NEPENTHE trial [NCT02780128]
15-11925a Osteosarcoma MCL1, CCNE1 Overexpression CDK4/6 Inhibitor
15-35162 Osteosarcoma CUL4A Overexpression NAE Inhibitor
14-71727 Osteosarcoma RAD51C c.24 T > G (p.F8L) PARP Inhibitor
15-83826 Osteosarcoma PDGFRA, KDR (VEGFR2) Overexpression MTKIb
13-21968 Congenital fibrosarcoma EML4-NTRK3 Fusion ALK Inhibitor
14-84044 Inflammatory
myofibroblastic tumor
VCAN-IL23R Fusion JAK Inhibitorb
aSame patient
bTargeted therapy received
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myeloid leukemia
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Table 3 Clinical utility beyond targetable somatic mutations
PIP ID Diagnosis Alteration Mutation (change) Clinical utility Implication
Sequence mutations
15-63375 AML changed to JMML PTPN11; SETB1 c.181G > T (p.D61Y);
c.2602G > A (p.D868N)
Diagnostic [31, 46] JMML
13-72282a T-ALL STAT5B c.2110A > C (p.I704L) Diagnostic [30, 47] Gamma-delta T-cell
lymphoma
15-26188 ALL NT5C2 c.1219G > T (p.D407Y) Pharmacogenomic
[32, 33]
Affects therapy
13-45348 AML IDH1 c.394C > T (p.R132C) Diagnostic [48, 49] Maffucci syndrome
14-53198 AML CEBPA c.939_940insAAG
(p.K313_V314insK);
c.326_327insC (p.P109fs)
Prognostic [50] Improved prognosis
15-10838 Glioma H3F3A c.83A > T (p.K28M) Prognostic [51] Poor prognosis
14-37237 Glioblastoma multiforme H3F3A c.83A > T (p.K28M) Prognostic [52, 53] GBM subgroup, K27
14-35585 Renal cell carcinoma VHL c.497 T > G (p.V166G) Diagnostic [54] Von Hippel Lindau
14-47205 Nephroblastomatosis PIK3CA c.1035 T > A (p.N345K) Diagnostic [55] Nephroblastomatosis
14-78154a Medulloblastoma KDM6A c.2989_2990dupAT
(p.M997fs)
Prognostic [56] Risk stratification, group 4
14-75899 Neuroblastoma ATRX c.5239delA (p.T1747fs) Prognostic [57] Poor prognosis
14-10141 Pleuropulmonaryblastoma DICER1 c.5438A > G (p.E1813G) Health Maintenance
[58]
DICER syndrome
Transcriptome analysis and CNV
14-24794 AML CBFB-MYH11 Fusion Prognostic [59] Low-risk stratification
15-64793 B-ALL FOXP1-ABL1 Fusion Prognostic [60] High-risk stratification
15-84578 AMKL CBFA2T3-GLIS2 Fusion Diagnostic [61];
Prognostic [35]
AMKL; Poor prognosis
14-85546 CML BCR-ABL1 Fusion Diagnostic [59] CML
13-72282a T-ALL Isochromosome 7q Copy number change Diagnostic [39] Gamma-delta
T-cell lymphoma




13-81192 Alveolar soft part sarcoma ASPSCR1-TFE3 Fusion Diagnostic [65] Alveolar soft part sarcoma
13-65217 Ewing sarcoma EWSR1-FLI1 Fusion Diagnostic [66] Ewing sarcoma
15-47087 Ewing sarcoma EWSR1-FLI1; Low expression
of PAX8, FHIT, CASP10, CHD2,
with high expression of







13-21968 Undifferentiated sarcoma EML4-NTRK3 Fusion Diagnostic [34] Infantile fibrosarcoma
16-88073 Ependymoma C11orf95-RELA; Alternating
gains and losses on chr 11









14-27243 Neuroblastoma MYCN amplified, deletion




Prognostic [69, 70] Risk-based therapy
14-42817 Neuroblastoma MYCN non-amplified,




Prognostic [69, 70] Risk-based therapy
15-39486 Neuroblastoma MYCN non-amplified, no




Prognostic [69, 70] Risk-based therapy
14-44070 Neuroblastoma MYCN amplified, loss of 1p,




Prognostic [69, 70] Risk-based therapy
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Germline variants classified as VOUS (Additional file 5:
Table S6) were not returned to patients except if they met
the following criteria: (1) the variant was predicted to be
destructive; (2) the variant was in a well validated cancer-
associated gene; and (3) a second somatic alteration was
identified or the variant was reduced to homozygosity in
the tumor. Clinical genetics returned a VOUS to four
patient families meeting these criteria, including an ITK
(p.V175V) mutation in a 7-year-old girl with Hodgkin
lymphoma and Epstein-Barr virus, an SDHC (p.G75D)
mutation was found in a 12-year-old boy with ALL, a
DICER1 (p.D609Y) mutation in an 18-year-old boy with
ALCL, and an APC (p.V1822D) mutation in a 7-year-old
boy with Ewing sarcoma.
Clinical impact of WES
To determine the overall clinical impact of NGS cancer
analysis, we evaluated each case as to whether the
sequencing data were of potential utility to the referring
physician in a clinically meaningful manner. Overall, clin-
ically impactful results were found in 67/101 cases (66%)
(Fig. 4). Potentially actionable alterations were found in
38% of cases. In 23% of the cases, the data obtained pro-
vided diagnostic significance. Importantly, germline pre-
disposition to cancer was identified in 14% of all cases.
WES and RNA-seq allows for significant additional
analytical endpoints (CNV, fusions, gene expression)
over targeted gene panels. Focusing on the 60 cases
with full tumor/normal WES and RNA-seq (cWES),
the resulting data were clinically impactful in 45 cases
(75%) (Fig. 5). A total of 72 potentially clinically impactful
results were found with cWES accounting for 85% of the
findings (tumor/normal WES: 45%, n = 32; RNA-seq: 40%,
n = 29) followed by CNV (7%, n = 5) and RNA-seq and
CNV together in 8% (n = 6). Of the 30 potentially target-
able aberrations found, 14 were by tumor/normal WES,
15 by RNA-seq, and one by CNV (Fig. 5).
Discussion
In this report, we reviewed the results of the first 101
patients evaluated in our precision cancer medicine
program. While we used a variety of analytical approaches
matched to the clinical indications, we primarily utilized a
combination of tumor/normal WES and tumor RNA-seq.
This platform provided several advantages over targeted
cancer gene panels, including the ability to identify trans-
locations, segmental chromosomal changes, and relative
gene expression changes.
Similar to other sequencing efforts in pediatric oncology,
we found that the overall mutational load in our patients
was relatively low by comparison to adult cancers [38]. Of
significance, we identified germline alterations that predis-
pose to cancer in 14% of our patients. This is slightly higher
than other studies that have demonstrated approximately
8.5–10% frequency of germline risk alleles in pediatric
oncology patients and may reflect a selection bias to se-
quence patients with high-risk cancers [12, 43, 44]. These
Table 3 Clinical utility beyond targetable somatic mutations (Continued)





Prognostic [71] Good prognosis
15-49177 Medulloblastoma IMPG2, GABRA5, LAPTM4B,
MAB21L2, NPR3, MFAP4, NRL,
ZFPM2, TSHZ3, IGF2BP3,
GALNT14, GPR98; Loss of
10q22.2-10qter involving
PTEN and SUFU, loss of
17p, gain of 17q
Overexpression;
Copy number change
Prognostic [72] Risk stratification,
subgroup 3/4
15-70532 Ependymoma Gain of 1q, loss of 6q Copy number change Prognostic [73–75] Poor prognosis
14-78154a Medulloblastoma KCNA1, RBM24, KLHL13, EN2,
SNCAIP, PDE1C, GRM8, KCNIP4,








Gain of chromosome 7,
LOH at 9p
Copy number change Diagnostic [76] Pleomorphic
xanthoastrocytoma
15-97336 Small round blue cell tumor EWSR1-WT1 Fusion Diagnostic [77] DSRCT
15-34296 Ependymoma TNC, CALB1, PLAG1,
ALDH1L1, RELN
Overexpression Prognostic [37] Risk stratification, group A,
poor prognosis








ALL acute lymphoblastic leukemia, AMKL acute megakaryoblastic leukemia, AML acute myeloid leukemia, ATRT atypical teratoid rhaboid tumor, CML chronic
myeloid leukemia, CNV copy number variation, JMML juvenile myelomonocytic leukemia
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results underscore the need to routinely incorporate germ-
line analysis for pediatric oncology patients.
Although there is a paucity of Tier 1 actionable
alterations in pediatric cancers, using a more lenient
definition of actionable which includes same gene–
different tumor type, likely pathogenic VOUS, and
assessment of both clinical and preclinical data,
resulted in the identification of potentially actionable
alterations in 38% of all patients. This is comparable
to other studies and may in itself be sufficient justifi-
cation for comprehensive genomic analysis in cancer
patients [10, 12, 15, 45]. Despite this finding, only
16% of patients received matched targeted therapy.
The ability to intervene with targeted therapies is
particularly challenging for pediatric patients. Many
newer drugs lack efficacy data in pediatric diseases or
safety data in children and are therefore not yet
approved for administration. Additionally, insurance
companies are not obligated to provide coverage for
the off-label use of these high-cost agents. Compas-
sionate use experimental therapies undergoing clinical
testing or recently approved agents for adults are also
rarely granted for pediatric patients. Finally, a number
of targeted agents are not anticipated to have single-
agent efficacy (e.g. MEK inhibition for RAS mutant
tumors). Together, the lack of pediatric experience
and opportunities with combination therapy represent
additional constraints in pediatric oncology.
Nevertheless, we believe that narrowing the definition of
benefit to the identification of actionable targets and
matched targeted therapy underestimates the potential
clinical utility of comprehensive genomic analysis. We
provide examples of genomic alterations that are not
actionable per se, but which have significant clinical impact
including for diagnostic, prognostic, or pharmacogenomics
purposes. Taking a broad view of clinical impact, it is not-
able that the data from our sequencing platform impacted
clinical decision-making in over two-thirds of all cases.
With the increase in genomic medicine programs and the
growing body of knowledge, the adoption of a more inclu-
sive definition of clinical utility that does not narrowly focus
on drug selection for patients with a specific biomarker is
an important point to consider when incorporating NGS
technologies into clinical practice.
Most cancer sequencing programs focus on interro-
gation of tumor DNA. It is notable that in our pro-
gram the transcriptome data were responsible for a
number of clinically impactful calls that were not evi-
dent from interrogating the DNA alone. In addition
to verifying variants identified in the DNA analysis,
the transcriptome was used to identify translocations
and was mined to identify signaling pathway activity.
Fig. 4 Clinically impactful results. The PIPseq experience yielded clinically impactful results in 67/101 cases. The Venn diagrams depict the
complexity of overlapping findings within patients. That is, a patient may have a single finding fitting more than one category, whereas
another patient may have a finding fitting one category and another finding fitting a different category. For example, results categorized as
Targetable/ Diagnostic (n = 6) are as follows: BCR-ABL1; IDH1; PIK3CA; EML4-NTRK3; [STAT5B, KRAS, JAK1/ STAT5B, i7q]; and [TMEM106B-BRAF/ gain
chr 7, LOH 9p], with non-bracketed results representing a single finding fitting two categories and results within brackets representing those that
were Targetable/ Diagnostic, respectively. Similarly, results categorized as Targetable/ Prognostic (n = 7) are as follows: FOXP1-ABL1; [TET2/ CEBPA];
[H3F3A, FGFR1/ H3F3A]; [NRAS/ MYCN amp, del 1p and 11q, gain 17q]; [c-KIT, TET2, FLT3, NRAS/ CBFB-MYH11]; [KRAS/ No LOH 1p11q]; and
[Gain 12q.14.1 involving CDK2/ H3F3A]. Individual patient results are provided in Tables 2, 3, and 4
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We generated a model from transcriptomes in our
database, allowing us to identify expression outliers.
We were also able to project the gene expression data
into existing gene expression datasets for classification
purposes, allowing us for example, to identify a BCR-
ABL1-like gene expression pattern. Therefore, asses-
sing tumor RNA is an important component of com-
prehensive genomic approaches and in our series
samples interrogated with both WES and RNA-seq
characterization resulted in clinically impactful data in
75% of cases.
The importance of assessing germline in addition to
cancer DNA is evident from the 14% incidence of germ-
line variants that may predispose to cancer. These find-
ings clearly have broad implications that impact not only
the patient but potentially the entire family. Moreover,
the identification of germline risk offers opportunities
for prevention and early screening and detection. It is
notable that given the opportunity to opt out of this
knowledge, nearly all families actively choose for the
return of these results, underscoring the fallacy of the
paternalistic view that families need to be protected
from learning these findings.
Finally, extending beyond a fuller appreciation for
the potential clinical impact of sequencing technolo-
gies, it is important to consider that genomic ap-
proaches do not just provide incremental data, but
may replace many conventional tests. Currently, many
genetic alterations can be identified by standard ap-
proaches, such as karyotype and FISH, and with faster
turnaround times. Similarly, existing NGS panels,
which allow the detection of mutations and/or fusions
of clear clinical relevance, may be adequate in certain
clinical scenarios. Nevertheless, in an era where initial
diagnostic biopsies are often performed through min-
imally invasive approaches, there is a compelling
Fig. 5 Clinical impact of WES and RNA-seq by sequencing technology. Sixty patients had full tumor/normal WES (including CNV) and RNA-seq
(cWES) performed. A total of 72 clinically impactful results were found in 45/60 cases (75%). A pie chart of the overall clinical impact of
cWES is presented on the left with a pie chart and table showing the number of impactful findings by sequencing technology on the right.
For six patients, CNV and overexpression together yielded prognostic information in four patients with neuroblastoma and two patients
with medulloblastoma
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argument to utilize comprehensive approaches with
minimal tissue requirements. As the cost of NGS de-
clines, the ability to comprehensively interrogate the
genome may supersede the need for sequential, po-
tentially tissue-exhausting directed testing, with the
added benefit of uncovering rare targetable and po-
tentially unexpected genomic drivers.
Conclusions
Our results demonstrate the feasibility of incorporating
clinical NGS into pediatric hematology-oncology prac-
tice. While the frequency of finding actionable alter-
ations is consistent with reports of other pediatric
oncology sequencing endeavors [10, 12, 15, 45], we feel
this singular attribute grossly underestimates the poten-
tial clinical utility of these data. The ability to avoid in-
effective/inappropriate therapies, to solidify a definitive
diagnosis, and to identify pharmacogenomics modifiers
all have clinical impact. Taking this more inclusive
view, it is striking that the sequencing data were found
to be clinically impactful in 66% of all cases tested
through our program and in 75% of cases comprehen-
sively assessed using cWES and RNA-seq. The value
proposition for next generation diagnostics, therefore,
should be measured both on the clinical impact of the
data and the ability to replace multiple conventional
single endpoint assays with a single comprehensive
view of the genome.
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